Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study

Fig. 4

Linaclotide mitigated IBS-C in individual patients to different extents, and the detected increase in the abundance of Blautia was effective at alleviating the symptoms of IBS-C caused by linaclotide. A Linear discriminant analysis (LDA) of effect size (LEfSe) was used to estimate the impact of the abundance of each component on the different effects between IBS-C patients and control individuals (healthy volunteers). B The abundance of Blautia at the genus level was highest in the 6-week group, followed by the control group (healthy volunteers), and the 0-week group had the lowest abundance. C, D Abundance of Blautia in the relief and no-relief patients before and after treatment. E Receiver operating characteristic (ROC) curve for the top twenty-one bacteria at the genus level and Blautia for separate prediction; the area under the curve (AUC) is shown

Back to article page